Delving into the Latest Updates on Azilsartan Kamedoxomil with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

azilsartan medoxomil, Azilsartan Medoxomil Potassium, AZM

+ [8]

Target

AT1R

Action

antagonists

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Essential HypertensionHypertension

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Takeda Pharma A/STakeda Pharma SA

Whan In Pharmaceutical Co., Ltd.

+ [3]

Inactive Organization

Takeda Pharmaceutical Co., Ltd.Arbor Pharmaceuticals, Inc.

AndersonBrecon, Inc.

License Organization

Celltrion, Inc.

Celltrion Healthcare Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (25 Feb 2011),

Hypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC30H24KN4O8

InChIKeyMIJNRHZSZJLCAG-UHFFFAOYSA-N

CAS Registry863031-24-7

ACEis are among the most widely used classes of antihypertensive drugs. ARBs have a similar antihypertensive efficacy and protective effect as ACEis, albeit with a somewhat different mechanism for RAS inhibition and a smaller randomized clinical trials' database. A difference between ACEis and ARBs is their tolerability profile, with ARBs having a rate of side effects similar to placebo. Most importantly, the clinical evidence supports a relevant protective role of ARBs toward the CV and renal damage development, as well as the occurrence of major adverse CV events, in hypertensive patients. Moreover, a neutral metabolic effect has been reported upon ARBs administration, in contrast to other antihypertensive agents, such as BBs and diuretics. These properties highlight the use of ARBs as an excellent pharmacological strategy to manage hypertension and its dangerous consequences
The purpose of this study is to compare pharmacokinetics (PK), safety, and tolerability of the IMPs Azilsartan medoxomil 80 mg tablets and of Edarbi® 80 mg tablets in healthy adult subjects of both sexes under fasting conditions.
Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of 20 mg to 320 mg after single or multiple dosing. In the present study the highest available strength of Azilsartan medoxomil 80 mg tablets will be investigated. Administration of this dose is expected to provide accurate and reliable determination of azilsartan plasma concentrations.
This is a single center, open label, randomized, four-period, two-sequence, fully replicate, cross-over bioequivalence study in healthy adult subjects of both sexes after single dose administration under fasting conditions. A single oral dose of the IMP (Test IMP: Azilsartan Medoxomil 80 mg tablets or Reference IMP: Edarbi® 80 mg tablets )will be administered under fasting conditions in each of the 4 study periods.

Start Date06 Jun 2025

Sponsor / Collaborator-

CTR20251635

/ RecruitingNot Applicable

美阿沙坦钾片在中国健康成年人中的一项随机、开放、空腹和餐后单次给药、两制剂、两周期交叉的生物等效性试验

[Translation] A randomized, open-label, single-dose, fasting and fed, two-formulation, two-period crossover bioequivalence study of Asartan Potassium Tablets in healthy Chinese adults

主要试验目的：考察单次口服(空腹/餐后)80mg受试制剂美阿沙坦钾片和参比制剂美阿沙坦钾片，在中国成年健康参与者体内的药代动力学特征，评估空腹与餐后条件下分别口服两种制剂的生物等效性。次要试验目的：评价受试制剂和参比制剂单次口服80mg(空腹/餐后)在中国成年健康参与者中的安全性。

[Translation]

Main study objectives: To investigate the pharmacokinetic characteristics of a single oral dose (fasting/postprandial) of 80 mg of the test preparation, mersartan potassium tablets and the reference preparation, mersartan potassium tablets in healthy adult Chinese participants, and to evaluate the bioequivalence of the two preparations under fasting and postprandial conditions. Secondary study objectives: To evaluate the safety of a single oral dose of 80 mg (fasting/postprandial) of the test preparation and the reference preparation in healthy adult Chinese participants.

Start Date15 May 2025

Sponsor / Collaborator

Shandong Xinhua Pharmaceutical Co., Ltd.

CTR20251115

/ Active, not recruitingNot Applicable

美阿沙坦钾片人体生物等效性研究

[Translation] Study on the bioequivalence of Asartan potassium tablets in healthy volunteers

本试验旨在研究单次空腹和餐后口服江苏天士力帝益药业有限公司研制、生产的美阿沙坦钾片（80 mg）的药代动力学特征；以Takeda Pharma A/S持证、Takeda Ireland Ltd.生产的美阿沙坦钾片（易达比®，80 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of single fasting and postprandial oral administration of Asartan Potassium Tablets (80 mg) developed and produced by Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.; using Asartan Potassium Tablets (Edabib®, 80 mg) licensed by Takeda Pharma A/S and produced by Takeda Ireland Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

Start Date31 Mar 2025

Sponsor / Collaborator

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil

Login to view more data

100 Translational Medicine associated with Azilsartan Kamedoxomil

Login to view more data

100 Patents (Medical) associated with Azilsartan Kamedoxomil

Login to view more data

1,053

Literatures (Medical) associated with Azilsartan Kamedoxomil

01 Jun 2025·CYTOTECHNOLOGY

Catalpol inhibits Hedgehog signaling pathway to suppress proliferation and promote lipid accumulation in rat meibomian gland epithelial cells

Article

Author: Zhang, Rui ; Liu, Zibin ; Lai, Jian

Supplementary Information:

The online version contains supplementary material available at 10.1007/s10616-025-00769-9.

01 Jun 2025·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Stability-indicating HPLC analysis of Azilsartan Medoxomil potassium: A QbD-based method development and validation

Article

Author: Hussain, Ujban ; Jaiswal, Shweta ; Belgamwar, Veena ; Zambre, Divya ; Sheikh, Sameer

Developing robust analytical methods for Azilsartan Medoxomil Potassium (AZM), a potent angiotensin II receptor antagonist, is essential due to its instability and limited aqueous solubility. This study aimed to establish and optimize a high-performance liquid chromatography (HPLC) method for the accurate and stability-indicating quantification of AZM and its impurities in the active pharmaceutical ingredient (API) and formulated drug products. Using an Analytical Quality by Design (A-QbD) framework, method parameters were optimized through a Central Composite Design (CCD), focusing on variables such as acetonitrile concentration, buffer pH, and flow rate to achieve desirable tailing factors and retention times. The validated method demonstrated high accuracy, precision, and sensitivity, with a linear response range of 10-50 μg/mL and limits of detection and quantification as low as 0.00607 and 0.01841 ng/mL, respectively. Forced degradation studies confirmed the method's selectivity and stability-indicating capabilities by identifying distinct degradation products under various stress conditions, including acidic, basic, oxidative, and photolytic environments. The validated HPLC method was successfully applied to a commercial AZM formulation, yielding assay values within acceptable limits for quality control. This study provides a reliable and robust analytical method that ensures the quality and stability of AZM throughout its lifecycle.

08 May 2025·JOURNAL OF MEDICINAL CHEMISTRY

Medoxomil Prodrug Strategies

Review

Author: Georg, Gunda I. ; Haque, Ehfazul

Drug discovery campaigns often face biopharmaceutical challenges, some of which can be solved by a prodrug approach. Prodrugs are enzymatically or chemically transformed in vivo to produce active drugs. Among these, medoxomil promoieties have been judiciously employed in multiple drug discovery campaigns, leading to three prodrugs gaining FDA approval: azilsartan medoxomil (6), olmesartan medoxomil (20), and ceftobiprole medocaril (29), and one approval in Japan: prulifloxacin (35). The promoiety can be easily appended to mask carboxylic acids, amines, zwitterionic compounds, and other polar groups, imparting lipophilicity to the parent compound. The promoiety has the added advantage of rapid and complete conversion to the parent drug by multiple enzymatic pathways across different tissues. The approach has been used for drugs spanning multiple classes to improve oral bioavailability, solubility, tissue localization, efflux, and side effect profiles. This Perspective analyzes the history and application of medoxomil prodrugs and discusses their potential for drug development.

7

News (Medical) associated with Azilsartan Kamedoxomil

06 Nov 2024

·pharma.economictimes.indiatimes.com

Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

New Delhi: The Central Drugs Standard Control Organisation ( CDSCO ) has identified over 50 drugs which have failed in the drug test. In its latest report, the controller said 50 drugs including Paracetamol are "not of standard quality" (NSQ). The report has also flagged calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd were specifically mentioned for quality concerns. The report listed a total of 48 drugs in the NSQ category, including a Gauze Roll Non Sterile Roller Bandage. NSQ alerts come from monthly random sampling conducted by state drug officers. Some of the medicines were produced by companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Additionally, the CDSCO shared another list that features five more drugs that failed quality tests. The pharmaceutical companies denied responsibility for these drugs. They claim they are "spurious," and one response from a company stated, "The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The product is purported to be spurious; however, the same is subjected to outcome of investigation." CDSCO NSQ Test: Full list of drugs and their manufacturers Here is the list of drugs that failed the CDSCO test along with the manufacturers: Amoxicillin And Potassium Clavulanate Tablets IP (Clavam 625) - M/s. Alkem Health Science Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625) - M/s. Meg Lifesciences Calcium And Vitamin D3 Tablets IP (Shelcal 500) - M/s. Pure & Cure Healthcare Pvt. Ltd. Metformin Hydrochloride Sustained-release Tablets IP (Glycimet-SR-500) - M/s. Scott-Edil Pharmacia Ltd. Vitamin B Complex with Vitamin C Softgels - M/s. Asoj Soft Caps Pvt. Ltd. Rifmin 550 (Rifaximin Tablets 550 mg) - M/s. Legen Healthcare Pantoprazole Gastro-Resistant and Domperidone Prolonged-Release Capsules IP (Pan - D) - M/s. Alkem Health Science Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd. Montair LC Kid (Montelukast Sodium & Levocetirizine Hydrochloride Dispersible Tablets) - M/s. Pure & Cure Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) (RL 500 ml) - M/s. Vision Parenteral Pvt. Ltd. Fexofenadine Hydrochloride Tablets IP 120 mg - M/s. Maxtar Bio-Genics Laxnorm Solution (Lactulose Solution USP) - M/s. Athens Life Sciences Heparin Sodium Injection 5000 Units (Hostranil Injection) - M/s. Health Biotech Ltd. Buflam Forte Suspension (Ibuprofen & Paracetamol Oral Suspension) - M/s. Ornate Pharma Pvt. Ltd. Cepodem XP 50 Dry Suspension (Cefpodoxime Proxetil and Potassium Clavulanate Oral Suspension) - M/s. Hetero Labs Limited Nimesulide, Paracetamol and Chlorzoxazone Tablets (NICIP MR) - M/s. HSN International Rolled Gauze (Non-Sterilized) - M/s. Blazon India Ciprofloxacin Tablets IP 500 mg (Ocif-500) - M/s. Ornate Labs Pvt. Ltd. Nimesulide, Phenylephrine Hydrochloride & Levocetirizine Dihydrochloride Tablets (Nunim-Cold) - M/s. Unispeed Pharmaceuticals Pvt. Ltd. Adrenaline Injection IP Sterile 1 ml - M/s. Alves Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) RL 500ml - M/s. Vision Parentral Pvt. Ltd. Vingel XL Pro Gel (Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate, and Menthol Gel) - M/s. Universal Twin Labs Atropine Sulphate Injection IP 2 ml - M/s. Nandani Medical Laboratories Pvt. Ltd. Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) - M/s. Daxin Pharmaceuticals Pvt. Ltd. Heparin Sodium Injection IP 25000 IU / 5ml - M/s. Scott-Edil Pharmacia Ltd. Cefepime & Tazobactam for Injection (Crupime - TZ Kid Injection) - M/s. Cosmas Research Lab. Ltd. Atropine Sulphate Injection IP (Atropine Sulphate) - M/s. Priya Pharmaceuticals Salbutamol, Bromhexine HCI, Guaifenesin and Menthol Syrup (Acozil Expectorant) - M/s. Antila Lifesciences Pvt. Ltd. Diclofenac Sodium IP - M/s. Sara Exports Ltd. Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) - M/s. Digital Vision Phenytoin Sodium Injection USP - M/s. Health Biotech Ltd. Paracetamol, Phenylephrine Hydrochloride and Cetirizine Hydrochloride Suspension (Cethel Cold DS Suspension) - M/s. Win Cure Pharma Calcium 500 mg with Vitamin D3 250 IU Tablets IP - M/s. Life Max Cancer Laboratories Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) - M/s. Malik Lifesciences Pvt. Ltd. Olmesartan Medoxomil Tablets IP 40 mg - M/s. Life Max Cancer Laboratories INFUSION SET-NV - M/s. Medivision Healthcare Telmisartan Tablets IP 40 mg - M/s. Life Max Cancer Laboratories Alprazolam Tablets IP 0.25 mg (Erazol-0.25 Tablets) - M/s. Elikem Pharmaceuticals Pvt. Ltd. Glimepiride Tablets IP (2 mg) - M/s. Mascot Health Series Pvt. Ltd. Calcium and Vitamin D3 Tablets IP - M/s. Unicure India Ltd. Metronidazole Tablets IP 400mg - M/s. Hindustan Antibiotics Ltd. Paziva -40 - M/s. Gnosis Pharmaceuticals Pvt. Ltd. Pantomed -40 - Digital Vision 176 Cefixime Oral Suspension IP (Dry Syrup) - Nestor Pharmaceuticals Ltd. Moxymed CV - Alexa Pharmaceuticals Frusemide Injection IP 20 mg - Nestor Pharmaceuticals Ltd. Kudajarishtam - Bala Herbals Tab Nodosis - Steadfast Medishield Pvt. Ltd. Haridrakhanda - Bhaskara Vilasam Vaidyasala Pantoprazole Inj. BP 40 mg - Kerala Medical Services Corporation Ltd. Yogaraja Guggulu - Bhaskara Vilasam Vaidyasala PANCEF-OF - Aglomed Ltd.

Drug Approval

05 Jul 2024

·www.pharmaindustrial-india.com

Zydus Gets Tentative Approval from USFDA for Azilsartan Medoxomil Tablets

Zydus Lifesciences Ltd. has secured a tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg (USRLD: Edarbi tablets). Azilsartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil tablets may be used either alone or in combination with other antihypertensive agents. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India. Azilsartan Medoxomil Tablets had annual sales of USD 89 mn in the United States. The group now has 398 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 26,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline.

Drug Approval

05 Jul 2024

·www.pharmaindustrial-india.com

Zydus Gets Tentative Approval from USFDA for Azilsartan Medoxomil Tablets

Zydus Lifesciences Ltd. has secured a tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg (USRLD: Edarbi tablets). Azilsartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil tablets may be used either alone or in combination with other antihypertensive agents. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India. Azilsartan Medoxomil Tablets had annual sales of USD 89 mn in the United States. The group now has 398 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 26,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline.

Drug Approval

100 Deals associated with Azilsartan Kamedoxomil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Azilsartan Kamedoxomil	C09CA09	DB08822

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	European Union	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	Iceland	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	Liechtenstein	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	Norway	Takeda Pharma A/S	07 Dec 2011
Hypertension	United States	Azurity Pharmaceuticals, Inc.	25 Feb 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	01 Jan 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESH2021	Not Applicable	Heart failure with normal ejection fraction \| Hypertension	-	Fixed-dose combination AZL-M/CLD	wgdiglkhye(unjjukopbo) = panivqnodr xtbevmusny (cwmakfnrfq, 8.7 - 12.3)	Positive	01 Apr 2021
				Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics	wgdiglkhye(unjjukopbo) = dfntjpabzw xtbevmusny (cwmakfnrfq, 9.2 - 12.8)
NCT02541669 (CTgov)	Phase 1	Hypertension	64	TAK-491 (Open Label: TAK-491 40 mg)	mqitmikusb(pvszqoyyee) = rcytvhqjak tdvtroxcms (sjuvcwbwaw, 25.0) View more	-	05 Feb 2020
				TAK-491 (Open Label: TAK-491 80 mg)	mqitmikusb(pvszqoyyee) = qpaoygrzqy tdvtroxcms (sjuvcwbwaw, 20.5) View more
NCT02791438 (CTgov)	Phase 3	Secondary hypertension \| Hypertension \| Essential Hypertension	27	Placebo+Azilsartan (Azilsartan 2.5 - 20 mg (Weight < 50 kg))	kryydweepe = lbbriljmso obqyapekrj (qqvbthxlqu, lofgpuqnts - jszcdickhs) View more	-	23 Dec 2019
				Placebo+Azilsartan (Azilsartan 5 - 40 mg (Weight ≥ 50 kg))	kryydweepe = hzjogyrdob obqyapekrj (qqvbthxlqu, mvuzlegwmg - bevvuobpvb) View more
NCT02517866 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Essential Hypertension	380	Azilsartan Medoxomil	tmlflyihvi = slsuudfmbj ktqnkhopti (pkwunhbxnf, avbhfmhoea - osxflgmknh) View more	-	01 Mar 2019
NCT02480764 (CTgov)	Phase 3	Essential Hypertension	612	Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	oihbwvehmy(erylmgtkka) = yunrodzysj kovypsrxts (epwpakuydn, 0.5123) View more	-	11 Feb 2019
				Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg)	oihbwvehmy(erylmgtkka) = ybvwxkjmzo kovypsrxts (epwpakuydn, 0.5010) View more
NCT00591773 (Pubmed \| J Renin Angiotensin Aldosterone Syst)	Phase 3	Essential Hypertension	551	Azilsartan medoxomil 40 mg plus chlorthalidone	jgimygfvgq(gwpvjvvduv) = ttwexaujsr edpeylxhpl (bbykjxslbs )	-	01 Jul 2018
				Azilsartan medoxomil 80 mg plus chlorthalidone	jgimygfvgq(gwpvjvvduv) = vfcvjixacl edpeylxhpl (bbykjxslbs )
ESH2018	Not Applicable	Metabolic Syndrome \| Hypertension	32	Azilsartan medoxomil 40 mg	xzfrkoyrss(jhrujjjldh) = xzszaglrqu pbbndfrksw (aqlhhxhqmm ) View more	Positive	01 Jun 2018
				Azilsartan medoxomil 80 mg	xzfrkoyrss(jhrujjjldh) = eooicyhfup pbbndfrksw (aqlhhxhqmm ) View more
NCT01774591 (CTgov)	Not Applicable	Hypertension	21	Azilsartan medoximil (Azilsartan Medoximil.)	nbmrryvtnn(yztndkuyiq) = ieuoykxkcw esvcqhrqck (tlxjbnvcnj, 14) View more	-	09 Nov 2017
				Placebo (Placebo)	nbmrryvtnn(yztndkuyiq) = fwfkpxxnmv esvcqhrqck (tlxjbnvcnj, 904) View more
[PP.12.25] (ESH2017)	Not Applicable	Diabetes Mellitus, Type 2 \| Hypertension	30	Azilsartan medoxomil 40 mg	hjcnkyeaiy(fwsobekaqv) = hsrsxmwkcl snchahlsyh (nsvtyngjgs )	Positive	01 Sep 2017
				Azilsartan medoxomil 80 mg	hjcnkyeaiy(fwsobekaqv) = zaffcpuhya snchahlsyh (nsvtyngjgs )
[PP.22.13] (ESH2017)	Not Applicable	Essential Hypertension	-	Azilsartan medoxomil 80 mg	orrotmufyf(lstpaktxvp) = bqrbzmnabb liwdxdbuqq (axgpmedfry, 1.8) View more	Positive	01 Sep 2017